Griflux

Quick links to important sections

Griflux

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Griflux

Quick Facts

Property Description
Active ingredient Carbocisteine (S-carboxymethyl-L-cysteine)
Form Syrup, Oral solution, Capsule, Tablet
Pharmacological class Mucolytic agent, Secretolytic drug
General purpose Reduces mucus viscosity for easier clearance
Origin Synthetic amino acid derivative

What Type of Medicine is Griflux and What is its Composition?

The pharmaceutical product Griflux is defined by its sole active ingredient, Carbocisteine, which is classified as a mucolytic agent and a secretolytic drug. This classification is clinically recognized for substances designed to modify the properties of thick respiratory secretions. Carbocisteine, chemically designated as S-carboxymethyl-L-cysteine, is a synthetic amino acid derivative, establishing it as a manufactured compound rather than a natural extract. It operates as a single-ingredient product, offered in both liquid forms, such as syrup and oral solution—often with formulations specifically targeted for pediatric use—and solid forms like capsules and tablets. The official ATC classification is R05CB03.


What is the General Purpose of Griflux?

The general purpose of this mucolytic agent is to provide relief by addressing the primary problem of overly thick and viscous respiratory secretions. Carbocisteine achieves this by modulating the structure of mucin glycoproteins, thereby reducing the mucus's stickiness and viscosity. This action is designed to support the body’s natural process of mucociliary clearance, making the congested secretions easier to expel and consequently alleviating the discomfort associated with restricted airways.

What side effects are possible with Griflux?

Griflux: Possible Side Effects and Safety Information

The safety profile of Griflux is defined by adverse reactions categorized by system-organ class and frequency, as outlined in official regulatory documents. Information provided strictly reflects documented adverse events and formal safety restrictions.

Adverse Reaction Scope

Adverse Reaction Category Frequency Classification
Gastrointestinal System Common (Diarrhea, Nausea, Vomiting)
Nervous System Common (Headache, Dizziness)
Skin and Subcutaneous Tissue Less Common (Hypersensitivity Reactions, Photosensitivity)

Serious Adverse Reactions: The regulatory profile highlights the risk of serious skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), hepatotoxicity (liver damage), and, rarely, blood disorders (e.g., agranulocytosis) or a lupus-like syndrome. These events, though rare, are considered clinically significant and require immediate attention.

Population-Specific Safety Considerations

  • Hepatic Impairment: Contraindicated in patients with severe liver dysfunction, as the drug's metabolism and the risk of hepatotoxicity may be altered.
  • Contraception: Griflux may reduce the effectiveness of hormonal contraceptives, necessitating the use of non-hormonal barrier methods during and for a specified period after treatment.
  • Alcohol Use: Concomitant use with alcohol is restricted due to the potential for a disulfiram-like reaction, characterized by flushing, nausea, and tachycardia.

Safety Monitoring and Restrictions

  • Monitoring Requirements: Periodic monitoring of liver function and renal function is advised, especially during extended courses of therapy, due to the documented risk of organ toxicity.
  • Sunlight Exposure: Patients are formally advised to limit exposure to natural and artificial sunlight (e.g., tanning beds) due to a risk of photosensitivity, which can manifest as severe sunburn or rash.

The established safety profile emphasizes the need to monitor for signs of hypersensitivity and organ-specific toxicity, particularly liver injury, throughout the course of treatment. The documented restrictions concerning alcohol use and hormonal contraception are essential components of the drug's formal risk management strategy.

Overdose and Emergency Response

Overdose and when to seek help

The information provided in official regulatory documents regarding an overdose of Griflux (Carbocisteine) is defined by a specific set of documented symptoms and required emergency actions.


Documented Overdose Manifestations

The most likely symptoms associated with taking an excessive dose are Gastrointestinal (GI) disturbances, which include gastralgia (stomach pain), nausea, vomiting, and diarrhea. These manifestations are the primary signs documented in the regulatory prescribing information.


Required Emergency Actions

Immediate medical attention must be sought if an overdose is suspected, especially if the dose ingested is significantly higher than recommended, such as when it exceeds 4 to 5 times the prescribed amount.

  • Antidote: Regulatory sources state there is no specific antidote known for Carbocisteine poisoning.
  • Management: Treatment consists of instituting supportive therapy and appropriate symptomatic treatment to manage the manifestations. Gastric lavage may be considered, followed by observation of the patient's condition.

Contacting a doctor or hospital immediately is the required action, and the patient is advised to bring the product container or label to provide necessary information to healthcare professionals.

Therapeutic Uses of Griflux

Griflux (Carbocisteine) is commonly used to help with thick phlegm (mucus or sputum) and may assist with managing symptoms related to physical discomfort. It is relevant in clinical settings that involve acute or unstable symptom patterns, including Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, Bronchiectasis, and is used in conditions where patients experience symptoms associated with Cystic Fibrosis.

The primary therapeutic benefit may contribute to easing the difficulty associated with clearing secretions. Griflux is applied in addressing symptom clusters that may become intense or disruptive, such as difficulty expectorating and mucus-related chest congestion. It provides supportive relief when symptoms interfere with routine activities, generally contributing to improved day-to-day comfort during symptomatic periods.

“Griflux is applied when conditions produce a significant symptomatic burden and when patients experience symptoms that create noticeable physiological strain.”

This medication is generally used as an adjunctive therapy, supports the patient during difficult episodes, and may help ease distress associated with retained phlegm in conditions characterized by periods of heightened symptoms.


Quick Fact: Relief for Viscous Secretions

Property Description
Target Symptom Difficulty expectorating thick, sticky phlegm
Key Supportive Role Provides support that helps ease the overall symptom burden
Target Conditions Chronic Bronchitis, COPD, Bronchiectasis
Context of Use Adjunctive therapy for chronic mucus hypersecretion

Eligibility and Restrictions for Use

Who Can and Cannot Use Griflux?

This section outlines the official population eligibility for Griflux (Carbocisteine), strictly based on regulatory documents.


Eligibility Status Summary

Category Regulatory Wording
Eligible Populations Adults and adolescents (ages 12 years and over); Children aged 2 to 12 years for liquid formulations.
Use Not Recommended Pregnant and breastfeeding women.
Contraindicated Children under 2 years of age; Patients with active peptic ulceration; Individuals with known hypersensitivity to Carbocisteine or excipients.

Specific Population Restrictions

Griflux is contraindicated for any individual with active peptic ulceration (gastric or duodenal ulcer), as this condition prohibits its use according to regulatory labeling. The medicine is also contraindicated for children under 2 years of age.

Use requires specific caution in certain populations. This includes elderly patients and individuals with a history of gastroduodenal ulcers or those taking concurrent medications known to cause gastrointestinal bleeding.

Furthermore, the official label states that the medicine is not recommended for women who are pregnant, especially during the first trimester, or for those who are breastfeeding, due to insufficient data to confirm safe use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Griflux (Carbocisteine) defines the product's interaction profile through functional restrictions and cautions regarding additive risks, rather than via metabolic or pharmacokinetic alterations.


Documented Interaction Restrictions

Classification Interacting Substance/Class Official Regulatory Statement
Pharmacodynamic Conflict Antitussive medicinal products (cough suppressants) Co-administration is not recommended [Source: HPRA SmPC].
Pharmacodynamic Conflict Medicinal products that inhibit bronchial secretion (e.g., anticholinergics) Co-administration is not recommended [Source: Irish SmPC].
Additive Safety Risk Medicines that cause gastrointestinal bleeding (e.g., NSAIDs, corticosteroids) Caution is formally recommended due to an additive risk of gastrointestinal bleeding [Source: MHRA/emc SmPC].

Pharmacokinetic and Other Considerations

No drug interactions have been identified in regulatory documents that alter the plasma concentration or exposure of Carbocisteine, such as those involving CYP enzymes or drug transporters. Consequently, no mandatory timing or separation requirements are specified in the official labeling. The caution regarding additive safety risk is specifically noted for certain populations, including the elderly concurrently taking medications known to cause gastrointestinal bleeding.

The interaction structure is therefore determined by avoiding pharmacodynamic antagonism and managing existing safety risks, not by metabolic or clearance considerations.

Mechanism of Action

Mucin Structure and Composition Modulation

This section covers the drug's core action on respiratory secretions. The mechanism involves the chemical disruption of disulfide bonds that cross-link mucus proteins, combined with the enzymatic up-regulation of sialyl transferase in airway cells. This dual action contributes to the reduction of viscoelasticity and adhesion within the mucus.


Physiological Clearance Enhancement

The subsequent mechanism focuses on the respiratory system's function. The reduction in thickness and elasticity of the mucus decreases the mechanical load exerted on the cilia lining the airways. This modification of mucus fluidity supports the rate and function of mucociliary clearance.


Cellular Cytoprotection and Anti-Inflammatory Signaling

In addition to mucus modification, the drug engages regulatory pathways that influence the state of the airway epithelium. It acts as a modulator by activating the Nrf2 antioxidant pathway and inhibiting pro-inflammatory cascades like NF-kappaB. This mechanism mediates a decrease in oxidative stress and the signaling associated with chronic epithelial inflammation.

Dosage and Administration Information

How Griflux is Used: Official Administration and Dosing Principles

Griflux, containing Carbocisteine, is used as an oral medication only, available in dosage forms such as capsules, tablets, and oral solutions or syrups. The standard usage protocol follows a two-phase, titrated dosing regimen to establish treatment.


Standard Adult Dosing and Frequency

The typical regimen for adults and older adults begins with a higher initial daily dose of 2250 mg of carbocisteine, which is administered in divided doses over the day. Once a response is observed, this dosage is generally reduced to a lower maintenance daily dose of 1500 mg, also taken in divided doses.


Age-Specific and Contextual Rules

Instruction Category Official Usage Principle
Pediatric Use The drug is contraindicated in children under two years of age; dosing for older children uses syrup or oral solution based on body weight.
Timing Constraint Certain formulations of the oral solution specify taking the medicine without meals.
Combination Constraint Administration is not recommended in combination with an antitussive (cough suppressant).
Missed Dose If a dose is missed, it should be taken as soon as remembered, but a double dose must not be taken to compensate.

The official instructions mandate that liquid doses be measured accurately with the device provided. This structured approach governs the standardized use of Griflux.

Recent Clinical Evidence

Research evidence / Overview of studies for Griflux


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research examined Griflux in individuals with stable Chronic Obstructive Pulmonary Disease (COPD), particularly those with a history of chronic mucus hypersecretion. The body of evidence in this area includes long-term, placebo-controlled clinical trials, where researchers monitored outcomes reflecting daily functioning and overall health over extended time intervals.

These studies monitored how the frequency of acute respiratory episodes, known as exacerbations, changed in the observed populations. Research describes patterns where participants reported a change in the frequency of these acute episodes in some of the populations studied. The studies monitored patient-reported outcomes describing perceived discomfort, along with outcomes reflecting daily functioning. Findings related to long-term lung function measures were mixed, and studies reported that measured changes did not reach statistical significance when compared to the control group.


Evidence for Use in Bronchiectasis

Research examined Griflux in individuals with non-Cystic Fibrosis bronchiectasis, a condition characterized by periods of heightened symptoms and functional limitations. The main clinical trials in this area were conducted to determine the rate of pulmonary exacerbations over a year. The research examined outcomes related to physical discomfort and episodic changes in symptom activity.

The findings for bronchiectasis were mixed. Earlier, smaller-scale studies did report some patterns of change in secondary outcomes. However, recent, larger, and higher-quality studies have been conducted, and studies reported that the mean number of exacerbations measured did not show a statistically significant difference when compared to the control group over the study period.


Evidence for Short-Term Symptomatic Relief

Research examined Griflux in contexts exploring how symptoms change over time during acute respiratory episodes, focusing on conditions associated with acute or disruptive episodes. Studies in this category were typically short-term and observed responses over defined time intervals to measure changes related to systemic or functional imbalance.

Research highlights changes measured during the study period, particularly related to the consistency of respiratory secretions. Studies consistently reported measurable physical changes in how thick the sputum was, indicating a physiological effect. Studies also described patterns where patients reported an evolution in their symptoms over a short duration.

Frequently Asked Questions (FAQ)

Common questions about Griflux (FAQ)


Q: How long does it usually take to notice any effects from Griflux?

Official product information indicates that the drug's mechanism of action—modulating mucus properties—begins immediately after administration. However, the exact amount of time required for a person to notice a substantial improvement in their symptoms is not clinically established and may vary. The noticeable change in symptoms may evolve over time.


Q: Does Griflux have any known interactions with common over-the-counter pain relievers?

Regulatory documents advise caution when combining Griflux with certain medicines that may increase the risk of gastrointestinal bleeding. This caution specifically includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids. Patients are generally advised to inform their healthcare provider about all medications, including any over-the-counter pain relievers, that they are using.


Q: Can people who are allergic to other medications use Griflux?

Official patient guidance states that a history of allergic reactions to any medicine, including Griflux or its non-active components, is a key piece of information for the prescriber to consider. This information is used to help ensure that the medicine is appropriate for safe use.


Q: Do official documents mention long-term effects of using Griflux?

Official regulatory information states that there is no evidence to suggest the medicine is harmful even when taken over an extended duration. Periodic monitoring of certain functions, such as liver and renal status, is sometimes advised during long-term courses of therapy.


Q: What is the pregnancy safety category of Griflux in regulatory documents?

Official documents advise that the medicine is not recommended during the first trimester of pregnancy due to insufficient data on potential effects. While some regulatory systems use letter categories, the specific documents for this drug may not assign a formal classification.


Q: Does Griflux need to be adjusted if a patient is taking multiple other medications?

Regulatory information notes that no mandatory dose adjustments or timing separation requirements are needed for the medicine's absorption or clearance. However, specific drug combinations that could cause pharmacodynamic conflicts or additive risks, such as antitussives, are not recommended or require caution.


Q: What does the evidence say about the effectiveness of Griflux?

Research evidence indicates that the drug has measurable effects on the consistency of respiratory secretions, which supports the body’s natural clearance process. Findings regarding some long-term outcomes, such as statistical significance in lung function improvements, have been mixed across various studies.


Q: Does Griflux interact with recreational substances (informational description)?

Official regulatory information specifically includes a restriction on the co-use of this medicine with alcohol. This is due to a documented risk of a disulfiram-like reaction, which can cause flushing, nausea, and rapid heart rate. Information on other recreational substances is not provided in official regulatory documents.


Q: Is Griflux generally considered to be well-tolerated?

Clinical trial data summarized by regulatory bodies indicate that the overall incidence of reported adverse events was low compared to control groups. The most frequently observed events involve minor gastrointestinal disturbances.


Q: Is Griflux considered a common or specialized type of medicine?

The medicine is classified as a mucolytic agent, which targets thick respiratory secretions. Historically, its legal status has varied by country, being available in some regions only by prescription and in others as an over-the-counter preparation.


Q: How is Griflux different from other drugs used for similar conditions?

Griflux is officially classified as a mucolytic agent that works by chemically breaking down specific bonds within mucus proteins. Other drugs used for similar conditions may operate through different mechanisms, such as increasing the fluid content of mucus or suppressing the cough reflex.


Q: Do I need to avoid certain foods while using Griflux?

Official guidance on the use of Griflux states that patients can generally eat and drink normally while taking this medicine. While certain formulations may specify taking the dose without a meal, there is no blanket prohibition on specific types of food.


Q: Is there a possibility of becoming dependent on Griflux?

Regulatory safety data and clinical reports indicate that no habit-forming or dependence tendencies have been reported for this medicine.


Q: Does Griflux affect sleep patterns?

General patient information suggests the medicine does not typically cause sleepiness. The common nervous system effects listed are headache and dizziness, though rare case reports of drowsiness have been noted in the context of specific drug combinations.


Q: Are there any specific safety classifications, like a Black Box Warning, associated with Griflux?

The specific classification known as a Boxed Warning is a regulatory designation primarily used by the U.S. Food and Drug Administration. As Griflux is not currently approved for use in the United States, it does not carry this specific classification.


Q: Is Griflux safe to use with dietary supplements like vitamins?

Official advice states there is not enough regulatory information to confirm the safety of taking the drug concurrently with complementary medicines, herbal remedies, or supplements. These products are not typically subject to the same testing and approval processes as prescription medicines.


Q: Is it possible for Griflux to cause changes in mood or anxiety levels?

General changes in mood or anxiety are not commonly listed as reported side effects in the official profile. However, regulatory adverse event reports have rarely noted psychiatric symptoms in complex cases, such as hallucinations.


Q: Does Griflux have a high risk of interaction with blood pressure medications?

Official regulatory documents defining drug-drug interaction risk do not list blood pressure medications as a specific class that is contraindicated or requires special caution.


Q: Is there a generic version of Griflux available?

The active ingredient, Carbocisteine, is a widely manufactured and available synthetic compound. It is distributed internationally under numerous generic labels and various brand names.


Q: What is the duration of action for Griflux described in scientific papers?

Scientific pharmacokinetic data reports that the medicine is cleared from the bloodstream with a plasma half-life of approximately 1.3 to 1.9 hours. The time for which the clinical effect remains fully active is not always established.


Q: Can patients with certain heart conditions use Griflux?

Official documents do not list common heart conditions as a formal contraindication for the medicine's use. However, some severe cardiac adverse events have been reported in clinical trials among patients who had pre-existing heart disease.


Q: Is Griflux used worldwide, or only in certain regions?

The drug is officially approved for use in numerous countries across Europe, Asia, and South America. However, regulatory documents indicate that it is currently not approved for marketing in the United States or Canada.


Q: Are there any special considerations for people with diabetes using Griflux?

Regulatory documents do not list a specific drug-disease interaction caution for diabetes. For individuals managing their sugar intake, some liquid formulations are available as a sugar-free syrup option.


Q: How quickly is Griflux typically removed from the body?

Scientific data related to the medicine's clearance indicates that it is removed from the bloodstream with a plasma half-life of approximately 1.3 to 1.9 hours. This figure describes the time it takes for the concentration in the plasma to be reduced by half.


Q: Does Griflux have any noted effects on vision?

Vision changes are not listed among the commonly reported side effects. Rare symptoms, such as redness of the eye, have been noted in adverse event reports as a potential initial sign of rare, serious skin reactions.


Q: Is Griflux a new drug or has it been available for a while?

The active ingredient, Carbocisteine, has been a commercially available compound since the 1950s. It received its initial licensing in major territories during the 1970s, indicating that it is a well-established medicine.

How should Griflux be stored and disposed of?

How to Store and Dispose of Griflux

Official regulatory documents define specific conditions for storing and disposing of Griflux (Carbocisteine) to maintain product quality and safety.


Storage Requirements

Griflux must be stored at room temperature, typically below 25 C to 30 C, as specified by the manufacturer's label. The liquid forms (syrup/solution) are generally directed not to be refrigerated or frozen.

  • Container Integrity: Always store the medicine in its original packaging to protect it from light and moisture, and ensure the bottle is kept tightly closed after use.
  • In-Use Stability: For oral solutions, the product has a limited period of stability after the bottle is first opened (e.g., 15 to 28 days), after which any remaining portion must be discarded.
  • Safety: This medicine must be stored out of the sight and reach of children.

️ Disposal Instructions

Unused or expired Griflux must be disposed of in accordance with local regulations for pharmaceutical waste. The official labeling mandates that the product must not be thrown away via household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Griflux found in:

A-Z Index: